Why the quality investor may take a look at ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN).

In this article we will dive into ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) as a possible candidate for quality investing. Investors should always do their own research, but we noticed ASTRAZENECA PLC-SPONS ADR showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.

Key Considerations for Quality Investors.

• Over the past 5 years, AZN has experienced impressive revenue growth, with 17.27% increase. This demonstrates the company's ability to effectively expand its top line and suggests a positive outlook for future revenue generation.
• AZN demonstrates impressive performance in terms of ROIC excluding cash and goodwill, with a 84.63% ratio. This highlights the company's efficient utilization of capital and its focus on maximizing returns for investors.
• With a favorable Debt/Free Cash Flow Ratio of 4.16, AZN showcases its sound financial discipline and cash flow management. This ratio indicates the company's ability to service its debt obligations while maintaining sufficient free cash flow for future investments or operational needs.
• The Profit Quality (5-year) of AZN stands at 772.0%, highlighting its ability to consistently generate reliable profits. This metric underscores the company's strong business fundamentals and reinforces its position as a financially stable entity.
• AZN has consistently achieved strong EBIT growth over the past 5 years, with a 27.35% increase. This underscores the company's effective management of its operating income and suggests a positive outlook for future profitability.
• AZN has achieved impressive EBIT 5-year growth, surpassing its Revenue 5-year growth. This indicates the company's ability to improve its profitability and operational efficiency, highlighting its strong financial performance.

Fundamental analysis of AZN

ChartMill assigns a proprietary Fundamental Rating to each stock. The score is computed daily by evaluating various fundamental indicators and properties. The score ranges from 0 to 10.

We assign a fundamental rating of 6 out of 10 to AZN. AZN was compared to 198 industry peers in the Pharmaceuticals industry. While AZN has a great profitability rating, there are quite some concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AZN.

Our latest full fundamental report of AZN contains the most current fundamental analsysis.

More ideas for quality investing can be found on ChartMill in our Caviar Cruise screen.

Keep in mind

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.